ERBB2 and breast carcinoma: Varchetta S (28) reported that the ADCC effect of trastuzumab was positively correlated with pathological remission rates in HER2-positive breast cancer patients, which suggested that enhancing the ADCC effect can optimize the efficacy of trastuzumab.